Henry J. Fuchs Sells 15,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 15,000 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the sale, the insider now directly owns 141,422 shares in the company, valued at approximately $12,798,691. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

BioMarin Pharmaceutical Inc. (BMRN) opened at 92.57 on Thursday. The stock’s 50 day moving average is $86.72 and its 200 day moving average is $89.48. The firm’s market cap is $16.22 billion. BioMarin Pharmaceutical Inc. has a one year low of $78.42 and a one year high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $317.50 million for the quarter, compared to analyst estimates of $311.41 million. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned ($2.61) EPS. On average, analysts predict that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Henry J. Fuchs Sells 15,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.chaffeybreeze.com/2017/09/21/henry-j-fuchs-sells-15000-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC lifted its position in shares of BioMarin Pharmaceutical by 13.6% in the 1st quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 125 shares during the period. Global X Management Co. LLC lifted its position in shares of BioMarin Pharmaceutical by 59.7% in the 1st quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 619 shares during the period. Korea Investment CORP lifted its position in shares of BioMarin Pharmaceutical by 143.5% in the 2nd quarter. Korea Investment CORP now owns 1,595 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 940 shares during the period. Mutual of America Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical by 20.0% in the 1st quarter. Mutual of America Capital Management LLC now owns 2,066 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 344 shares during the period. Finally, Toronto Dominion Bank lifted its position in shares of BioMarin Pharmaceutical by 12.9% in the 2nd quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 243 shares during the period. 97.46% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, September 14th. They set an “overweight” rating and a $113.00 target price on the stock. ValuEngine raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Royal Bank Of Canada assumed coverage on shares of BioMarin Pharmaceutical in a research note on Thursday, September 14th. They set a “sector perform” rating and a $93.00 target price on the stock. BMO Capital Markets reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Friday, September 15th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $105.00 target price on the stock in a research note on Monday, July 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $109.09.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply